Poland vs United Kingdom of Great Britain and Northern Ireland: Pharmaceutical consumption
Pharmaceutical consumption over time
- Poland
- United Kingdom of Great Britain and Northern Ireland
How they compare
United Kingdom of Great Britain and Northern Ireland currently reports 308.8 Defined daily dose per 1 000 inhabitants per day against 175.6 Defined daily dose per 1 000 inhabitants per day in Poland, a difference of 133.2 Defined daily dose per 1 000 inhabitants per day.
That makes United Kingdom of Great Britain and Northern Ireland's figure about 1.8 times Poland's.
Across all 6 years both countries report, United Kingdom of Great Britain and Northern Ireland has been ahead every year.
Poland ranks 9th and United Kingdom of Great Britain and Northern Ireland ranks 12th of 9 groups.
United Kingdom of Great Britain and Northern Ireland has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Poland | United Kingdom of Great Britain and Northern Ireland | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 130.4 Defined daily dose per 1 000 inhabitants per day | 248.9 Defined daily dose per 1 000 inhabitants per day | 118.5 Defined daily dose per 1 000 inhabitants per day | United Kingdom of Great Britain and Northern Ireland |
| 2020s | 145.62 Defined daily dose per 1 000 inhabitants per day | 278.94 Defined daily dose per 1 000 inhabitants per day | 133.32 Defined daily dose per 1 000 inhabitants per day | United Kingdom of Great Britain and Northern Ireland |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher pharmaceutical consumption, Poland or United Kingdom of Great Britain and Northern Ireland?
- United Kingdom of Great Britain and Northern Ireland, at 308.8 Defined daily dose per 1 000 inhabitants per day against 175.6 Defined daily dose per 1 000 inhabitants per day in Poland as of 2024.
- What is the difference in pharmaceutical consumption between Poland and United Kingdom of Great Britain and Northern Ireland?
- 133.2 Defined daily dose per 1 000 inhabitants per day, with United Kingdom of Great Britain and Northern Ireland ahead.
- How many years of comparable data are there for Poland and United Kingdom of Great Britain and Northern Ireland?
- 6 years are reported by both, from 2019 to 2024.
- How do Poland and United Kingdom of Great Britain and Northern Ireland rank globally for pharmaceutical consumption?
- Poland ranks 9th and United Kingdom of Great Britain and Northern Ireland ranks 12th of 9 groups.
- Where does this data come from?
- Organisation for Economic Co-operation and Development, published as Pharmaceutical consumption. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Total pharmaceutical consumption according to the Anatomical Therapeutic Chemical (ATC) classification/Defined Daily Dose (DDD) system, created by the WHO Collaborating Centre for Drug Statistics Methodology. The unit of measurement is Defined Daily Dose (DDD), defined as the assumed average maintenance dose per day for a drug used on its main indication in adults. The Anatomical Therapeutic Chemical classification system divides drugs into different groups according to the organ system on which they act and/or therapeutical, pharmacological and chemical characteristics. The main principles for the classification of medicinal substances according to the ATC is presented in the publication “Guidelines for ATC classification and DDD assignment”, WHO Collaborating Centre for Drug Statistics Methodology, Oslo. The publication “ATC Index with DDDs” lists all assigned ATC codes and DDD values. Both these publications are updated annually. The ATC codes are based on the 2026 version of the ATC Index. All alterations implemented from January 2026 are available on the WHO Collaborating Centre for Drug Statistics Methodology website at https://www.whocc.no/lists_of__temporary_atc_ddds_and_alterations/. Data should reflect, where possible, the total consumption for each pharmaceutical drug category, i.e. including consumption in hospitals. Please refer to the Sources and Methods for detailed country-specific information.